-
1.发明公开
公开(公告)号：EP4269439A2
公开(公告)日：2023-11-01
申请号：EP23184844.1
申请日：2017-09-08
IPC分类号： C07K16/28
摘要： The present specification discloses a pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS. The pharmaceutical composition is administered by a dosage regimen comprising at least one course of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session of non-treatment.
-
公开(公告)号：EP3911954A1
公开(公告)日：2021-11-24
申请号：EP20742039.9
申请日：2020-01-16
发明人： EISENBACH-SCHWARTZ, Michal , BEN-YEHUDA, Hila , ARAD, Michal , CROESE, Tommaso , PERALTA RAMOS, Javier Maria , CASTELLANI, Giulia , ROSENZWEIG, Neta
IPC分类号： G01N33/567 , C07K14/705 , C07K14/52 , G16H20/10
-
3.发明公开
公开(公告)号：EP3322443A1
公开(公告)日：2018-05-23
申请号：EP16753707.5
申请日：2016-07-13
IPC分类号： A61K39/395 , A61K38/00 , A61K39/00
CPC分类号： A61K39/395 , A61K38/00 , A61K38/005 , A61K39/39541 , A61K2039/545 , A61K2039/572 , A61K2121/00
摘要： A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual by release of a restraint imposed on the immune system by one or more immune checkpoints, for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing- remitting multiple sclerosis (RRMS), and said one or more immune checkpoints is selected from the group consisting of ICOS-B7RP1, V-domain Ig suppressor of T cell activation (VISTA), B7- CD28-like molecule, CD40L-CD40, CD28-CD80, CD28-CD86, B7H3, B7H4, B7H7, BTLA- HVEM, CD137-CD137L, OX40L, CD27-CD70, STimulator of INterferon Genes (STING), T cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain (TIGIT) and A2a R-Adenosine and indoleamine-2,3-dioxygenase (IDO)-L-tryptophan is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session of non-treatment.
-
4.发明公开REDUCING SYSTEMIC REGULATORY T CELL LEVELS OR ACTIVITY FOR TREATMENT OF DISEASE AND INJURY OF THE CNS 审中-公开系统性调节性T细胞的浓度的减少和活动的中枢神经系统疾病或损伤的治疗
公开(公告)号：EP3116542A2
公开(公告)日：2017-01-18
申请号：EP15731728.0
申请日：2015-03-12
CPC分类号： C07K16/2803 , A61K31/404 , A61K31/4155 , A61K31/7068 , A61K33/36 , A61K38/00 , A61K38/005 , A61K38/02 , A61K38/14 , A61K38/168 , A61K38/18 , A61K38/208 , A61K39/395 , A61K39/39541 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/507 , A61K2039/545 , A61K2039/57 , A61K2039/572 , A61K2121/00 , C07K16/2818 , C07K16/2827 , C07K2317/21 , C07K2317/24 , C07K2317/75 , C07K2317/76 , A61K2300/00
摘要： A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session.
摘要翻译： 包含活性剂的硬化的药物组合物做的原因减少全身免疫抑制的水平的个体用于治疗疾病，障碍，病症或CNS的损伤根本不包括自身免疫神经炎疾病，复发缓解型多发性（RRMS ），提供了一种。 所述药物组合物通过的剂量方案，其包括治疗的至少两个疗程，治疗，依序包括随后在间隔会话的处理会话的每个过程是针对施用。
-
5.发明公开INDIVIDUALIZED IMMUNOMODULATION THERAPY FOR NEURODEGENERATIVE DISORDERS, CNS INJURY AND AGE-RELATED DEMENTIA 审中-公开PERSONALIZED免疫调节治疗神经退行性疾病，中枢神经系统病变和年龄相关性痴呆
公开(公告)号：EP2892353A1
公开(公告)日：2015-07-15
申请号：EP13836112.6
申请日：2013-09-10
发明人： EISENBACH-SCHWARTZ, Michal , FRIEDMAN, Nir , BARUCH, Kuti , KUNIS, Gilad , CAHALON, Liora , ROSENZWEIG, Neta , DECZKOWSKA, Aleksandra
CPC分类号： A61K39/0007 , A61K35/17 , A61K38/217 , A61K45/06 , A61K2039/55544 , A61K2039/55561 , A61K2039/55566 , A61K2039/57 , A61P25/28 , C07K16/2878 , C07K2317/76 , C12N5/0636 , C12N15/117 , C12N2310/17 , C12N2320/30 , C12N2501/2304 , C12N2501/2306 , C12N2501/231 , C12N2501/2317 , C12N2501/24 , C12N2501/25 , A61K2300/00
摘要： A method for treating a disease, disorder, condition or injury of the Central Nervous System (CNS) in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of an active ingredient, such as a non-encephalitogenic or weakly encephalitogenic combination of a Th1 adjuvant and a CNS-specific antigen, causing activation of the choroid plexus of said subject and maintaining said activation by reducing immunosuppression and establishing Th1-type immune response at the choroid plexus thus allowing either anti-inflammatory immune cells or immune cells which acquire a healing phenotype at the cerebrospinal fluid to pass through the choroid plexus, and accumulate at a site of damage in the CNS caused by said disease, disorder, condition or injury is provided.
-
6.发明公开
公开(公告)号：EP4269439A3
公开(公告)日：2024-01-17
申请号：EP23184844.1
申请日：2017-09-08
IPC分类号： A61K39/395 , A61P25/28 , A61P27/00 , C07K16/28
摘要： The present specification discloses a pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS. The pharmaceutical composition is administered by a dosage regimen comprising at least one course of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session of non-treatment.
-
7.发明公开
公开(公告)号：EP3509636A1
公开(公告)日：2019-07-17
申请号：EP17848290.7
申请日：2017-09-08
IPC分类号： A61K39/395 , A61P25/28 , A61P27/00 , C07K16/28
-
8.发明公开T-HELPER 1 ADJUVANT FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS 审中-公开T-HELPER 1辅助剂治疗AMYOTRTRHIC横向性SCLEROSIS
公开(公告)号：EP3320914A1
公开(公告)日：2018-05-16
申请号：EP17209271.0
申请日：2013-09-10
发明人： EISENBACH-SCHWARTZ, Michal , FRIEDMAN, Nir , BARUCH, Kuti , KUNIS, Gilad , CAHALON, Liora , ROSENZWEIG, Neta , DECZKOWSKA, Aleksandra
IPC分类号： A61K38/21 , A61K39/00 , A61K45/06 , C12N5/00 , A61P25/00 , A61P25/28 , A61K35/17 , C12N5/0783 , C12N15/117
CPC分类号： A61K39/0007 , A61K35/17 , A61K38/217 , A61K45/06 , A61K2039/55544 , A61K2039/55561 , A61K2039/55566 , A61K2039/57 , A61P25/28 , C07K16/2878 , C07K2317/76 , C12N5/0636 , C12N15/117 , C12N2310/17 , C12N2320/30 , C12N2501/2304 , C12N2501/2306 , C12N2501/231 , C12N2501/2317 , C12N2501/24 , C12N2501/25 , A61K2300/00
摘要： A method for treating a disease, disorder, condition or injury of the Central Nervous System (CNS) in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of an active ingredient, such as a non-encephalitogenic or weakly encephalitogenic combination of a Th1 adjuvant and a CNS-specific antigen, causing activation of the choroid plexus of said subject and maintaining said activation by reducing immunosuppression and establishing Th1-type immune response at the choroid plexus thus allowing either anti-inflammatory immune cells or immune cells which acquire a healing phenotype at the cerebrospinal fluid to pass through the choroid plexus, and accumulate at a site of damage in the CNS caused by said disease, disorder, condition or injury is provided.
摘要翻译： 一种治疗有需要的受试者的中枢神经系统（CNS）的疾病，病症，病症或损伤的方法，其包括向所述受试者施用治疗有效量的活性成分，例如非脑炎或弱致脑炎 Th1佐剂和CNS特异性抗原的组合，引起所述受试者脉络丛的激活，并通过减少免疫抑制并在脉络丛中建立Th1型免疫应答来维持所述活化，从而使得抗炎免疫细胞或免疫细胞 其在脑脊液获得愈合表型以穿过脉络丛，并且积聚在由所述疾病，病症，病症或损伤引起的CNS损伤部位处。
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.014 秒)
